Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Stock Symbol NASDAQ:KOD ; Valuation at IPO $365M; Money Raised at IPO $90M; IPO Share Price $10.00; IPO Date Oct 3, 2018 Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.
Everything you need to know about the Kodiak Sciences IPO including Offer Price, Filed Date, IPO Date, Offer Shares, Dealsize and Underwriters. At Kodiak, we are developing disruptive products and platforms to prevent and treat the leading causes of blindnessWe aspire to global leadership in ophthalmology through internal focus and by aggregating top talent, technologies, discoveries and ideas.Some of the statements on this site are forward-looking. Kodiak Sciences Inc. operates as a clinical stage biopharmaceutical company. Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Some of the statements on this site are forward-looking. Kodiak Sciences is registered under the ticker NASDAQ:KOD . Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated).
When did Kodiak Sciences IPO? KOD IPO Price: (view offering) | KOD IPO Date: | Industry: | View info for the Kodiak Sciences Inc. IPO at ClickIPO. Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.